Section Arrow
Quote
LCTX.NYSE-M
- Lineage Cell Therapeutics
Quotes are at least 15-min delayed:2026/04/16 14:28 EDT
Regular Hours
Last
 1.64
+0.01 (+0.61%)
Day High 
1.64 
Prev. Close
1.63 
1-M High
1.685 
Volume 
558.53K 
Bid
1.63
Ask
1.64
Day Low
1.56 
Open
1.63 
1-M Low
1.42 
Market Cap 
406.01M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.55 
20-SMA 1.53 
50-SMA 1.67 
52-W High 2.09 
52-W Low 0.4 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.28/-0.10
Enterprise Value
407.58M
Balance Sheet
Book Value Per Share
0.18
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
14.56M
Operating Revenue Per Share
0.04
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.5848+0.0408+7.50%-- 
PBMPsyence Biomedical Ltd.6.9+4.02+139.58%-- 
ALLOAllogene Therapeutics2.33+0.16+7.37%-- 
ATAIAtaiBeckley Inc4.105+0.105+2.63%-- 
IBRXImmunityBio7.16-0.62-7.97%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.